Combination therapy for inoperable bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two medications (envafolimab and surufatinib) plus a procedure that uses heat to destroy cancer cells inside the bile ducts. It is for people with bile duct or gallbladder cancer that cannot be removed surgically and who are not candidates for or do not want chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 79 years old.
- You must have been diagnosed with bile duct or gallbladder cancer (biliary tract cancer).
- You should not have had previous treatment for this cancer, and you must not be eligible for curative surgery.
- You must either be unable to take chemotherapy or have decided not to.
- You need to be in good enough health to do most daily activities (a score of 0 or 1 on the ECOG scale).
- You must not have an active autoimmune disease or have had one in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with bile duct cancer that cannot be removed by surgery or has spread. The treatment combines a targeted drug (surufatinib) with immunotherapy and chemotherapy to try to shrink tumors and improve outcomes.
This trial tests a combination of a targeted therapy (surufatinib), chemotherapy (gemcitabine and cisplatin), and an immunotherapy (durvalumab or pembrolizumab) for people with advanced bile duct cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination can shrink tumors and improve outcomes.
This study tests a combination of two drugs (surufatinib and toripalimab) plus a chemo infusion directly into the liver (HAIC) for people with bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new immunotherapy drug called envafolimab for people with advanced bile duct or gallbladder cancer. The goal is to see if it can help shrink tumors or slow the disease.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
Hear when a new Unresectable Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.